Quang Vinh Truong

US Patent:

7390835, Jun 24, 2008

Filed:

Oct 27, 2004

Appl. No.:

10/576381

Inventors:

Shrenik K. Shah - Metuchen NJ, US
Quang T. Truong - Metuchen NJ, US
Hongbo Qi - Edison NJ, US
William K. Hagmann - Westfield NJ, US

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

C07C 211/00
A01N 33/00

US Classification:

514579, 564336

Abstract:

Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, including alcohol and nicotine addiction, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.

US Patent:

7572785, Aug 11, 2009

Filed:

Nov 3, 2005

Appl. No.:

11/265850

Inventors:

Paul E. Finke - Milltown NJ, US
Sander G. Mills - Scotch Plains NJ, US
Christopher W. Plummer - Keasbey NJ, US
Shrenik K. Shah - Metuchen NJ, US
Quang T. Truong - Edison NJ, US

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

A61K 31/55
C07D 405/00
C07D 413/00

US Classification:

51421709, 51423518, 514326, 544141, 546210

Abstract:

The use of compounds of the present invention as antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor particularly in the treatment, prevention and suppression of diseases mediated by the Cannabinoid-1 (CB1) receptor. The invention is concerned with the use of these novel compounds to selectively antagonize the Cannabinoid-1 (CB1) receptor. As such, compounds of the present invention are useful as psychotropic drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, particularly to opiates, alcohol, and nicotine. The compounds are also useful for the treatment of obesity or eating disorders associated with excessive food intake and complications associated therewith.

US Patent:

20030114495, Jun 19, 2003

Filed:

Jul 17, 2002

Appl. No.:

10/198442

Inventors:

Paul Finke - Milltown NJ, US
Sander Mills - Scotch Plains NJ, US
Christopher Plummer - Keasbey NJ, US
Shrenik Shah - Metuchen NJ, US
Quang Truong - Edison NJ, US

International Classification:

A61K031/4439
A61K031/4172
A61K031/4178

US Classification:

514/341000, 514/397000, 514/400000

Abstract:

The use of compounds of the present invention as antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor particularly in the treatment, prevention and suppression of diseases mediated by the Cannabinoid-1 (CB1) receptor. The invention is concerned with the use of these novel compounds to selectively antagonize the Cannabinoid-1 (CB1) receptor. As such, compounds of the present invention are useful as psychotropic drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, particularly to opiates, alcohol, and nicotine. The compounds are also useful for the treatment of obesity or eating disorders associated with excessive food intake and complications associated therewith. Novel compounds of structural formula (I) are also claimed.

US Patent:

20100184758, Jul 22, 2010

Filed:

Jul 15, 2008

Appl. No.:

12/668822

Inventors:

Peter H. Dobbelaar - Morris Plains NJ, US
Wu Du - Monroe Township NJ, US
Liangqin Guo - Edison NJ, US
William K. Hagmann - Westfield NJ, US
Shuwen He - Edison NJ, US
Tianying Jian - Westfield NJ, US
Jian Liu - Edison NJ, US
Ravi P. Nargund - East Brunswick NJ, US
Alexander Pasternak - Princeton NJ, US
Shrenik K. Shah - Metuchen NJ, US
Quang T. Truong - Morganville NJ, US
Zhixiong Ye - Princeton NJ, US
Raman Bakshi - Edison NJ, US

International Classification:

A61K 31/5377
C07D 471/14
A61K 31/437
C07D 413/14
C07D 403/14
A61K 31/501
A61K 31/4995
A61K 31/506
A61P 3/10
A61P 3/04
A61P 3/00
A61P 3/06
A61P 9/12

US Classification:

5142328, 546 84, 514292, 544126, 544238, 51425204, 544361, 51425303, 544333, 514256, 544315, 514274

Abstract:

Beta-carboline derivatives of structural formula I are selective antagonists of the somatostatin subtype receptor 3 (SSTR3) and are useful for the treatment of Type 2 diabetes mellitus and of conditions that are often associated with this disease, including hyperglycemia, insulin resistance, obesity, lipid disorders, and hypertension. The compounds are also useful for the treatment of depression and anxiety.

US Patent:

20120264777, Oct 18, 2012

Filed:

Jan 11, 2011

Appl. No.:

13/518015

Inventors:

Liangqin Guo - Edison NJ, US
William K. Hagmann - Westfield NJ, US
Shuwen He - Edison NJ, US
Zhong Lai - Scotch Plains NJ, US
Jian Liu - Edison NJ, US
Ravi P. Nargund - East Brunswick NJ, US
Shrenik K. Shah - Metuchen NJ, US
Quang T. Truong - Morganville NJ, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

A61K 31/437
A61P 3/10
A61P 9/12
A61P 3/04
A61P 3/06
A61P 3/00
C07D 471/04
A61P 5/48

US Classification:

514292, 546 87

Abstract:

Beta-carboline derivatives of structural formula I are selective antagonists of the somatostatin sub-type receptor 3 (SSTR3) and are useful for the treatment of Type 2 diabetes mellitus and of conditions that are often associated with this disease, including hyperglycemia, insulin resistance, obesity, lipid disorders, and hypertension. The compounds are also useful for the treatment of depression and anxiety.

US Patent:

20170114065, Apr 27, 2017

Filed:

May 28, 2015

Appl. No.:

15/315082

Inventors:

- Rahway NJ, US
Jared N. Cumming - Garwood NJ, US
Shuwen He - Fanwood NJ, US
Brandon M. Taoka - Hoboken NJ, US
Quang T. Truong - Morganville NJ, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

C07D 487/04
C07D 471/04

Abstract:

In its many embodiments, the present invention provides certain C2-carbocyclic iminothiazine dioxide compounds, including compounds Formula (I); or a tautomers thereof, and pharmaceutically acceptable salts of said compounds and said tautomers, wherein R, R, ring A, R, m, ring B, RB, n, ring C, Rand p are as defined herein. The novel compounds of the invention are useful as BACE inhibitors and/or for the treatment and prevention of various pathologies related thereto. Pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other active agents), and methods for their preparation and use, including for the possible treatment of Alzheimer's disease, are also disclosed.

US Patent:

20160122380, May 5, 2016

Filed:

Jun 16, 2014

Appl. No.:

14/899008

Inventors:

- Rahway NJ, US
Vinay Girijavallabhan - Denville NJ, US
Quang Truong - Morganville NJ, US
Ping Chen - Edison NJ, US
Frank Bennett - Cranford NJ, US
Angela Kerekes - Plainfield NJ, US
Qun Dang - Westfield NJ, US
David B. Olsen - Lansdale PA, US
Ian Davies - Princeton NJ, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

C07H 19/10
A61K 45/06
A61K 31/7072

Abstract:

The present invention relates to Cyclic Phosphonate Substituted Nucleoside Derivatives of Formula (I): (structure) and pharmaceutically acceptable salts thereof, wherein B, X, R1, R2 and R3 are as defined herein, as well as to compositions and methods of using the Cyclic Phosphonate Substituted Nucleoside Derivatives for treating or preventing HCV infection in a patient.

US Patent:

20140128339, May 8, 2014

Filed:

Oct 15, 2013

Appl. No.:

14/054424

Inventors:

Vinay Girijavallabhan - Whippany NJ, US
Stephane Bogen - Somerset NJ, US
Quang T. Truong - Morganville NJ, US
Ping Chen - Edison NJ, US
Angela Kerekes - Plainfield NJ, US
Frank Bennett - Cranford NJ, US
Sara Esposite - Neptune NJ, US
Qingmei Hong - Scotch Plains NJ, US
Ian Davies - Princeton NJ, US

International Classification:

C07H 19/06
A61K 45/06
A61K 31/7072
C07H 19/10
A61K 31/7068

US Classification:

514 51, 536 2851, 536 285, 536 2853, 536 268, 536 2626, 514 49, 514 50

Abstract:

The present invention relates to 2′-Methyl Substituted Nucleoside Derivatives of Formula (I):and pharmaceutically acceptable salts thereof, wherein R, R, Rand R, are as defined herein. The present invention also relates to compositions comprising at least one 2′-Methyl Substituted Nucleoside Derivative, and methods of using the 2′-Methyl Substituted Nucleoside Derivatives for treating or preventing HCV infection in a patient.